...
首页> 外文期刊>Virchows Archiv >P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ
【24h】

P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ

机译:P-cadherin和cytokeratin 5:有用的辅助标记物,可原位区分基底样导管癌

获取原文
获取原文并翻译 | 示例
           

摘要

Gene expression profiles of invasive breast carcinomas have identified a subgroup of tumours with worse prognosis, which have been called “basal-like”. These are characterized by a specific pattern of expression, being estrogen receptor (ER) and HER2 negative, and frequently expressing at least one basal marker such as basal cytokeratins or epidermal growth factor receptor (EGFR). Previously, our group characterized basal-like tumours in a series of invasive breast carcinomas using P-cadherin (P-CD), p63 and cytokeratin 5 (CK5). Based on that study, we hypothesized that those high-grade basal-like invasive carcinomas might have a pre-invasive counterpart, which could be identified using the same approach. A series of 79 ductal carcinomas in situ (DCIS) were classified into distinct subgroups according to their ER, HER2 and basal markers expression. Luminal DCIS expressed ER and constituted 64.6% of the series; the HER2 overexpressing tumours did not express ER and represented 25.3% of the cases, whereas 10.1% lack the expression of ER and HER2 and expressed at least one basal marker (P-CD, CK5, CK14, p63, vimentin and/or EGFR). These basal-like DCIS were mostly high-grade, with comedo-type necrosis, and consistently showed expression of P-CD and CK5. In conclusion, DCIS with a basal-like phenotype represent a small percentage in our series, being P-CD and CK5, the most useful adjunct markers to distinguish this subset of carcinomas in situ of the breast.
机译:浸润性乳腺癌的基因表达谱已鉴定出预后较差的肿瘤亚组,被称为“基底样”。它们的特征在于特定的表达模式,即雌激素受体(ER)和HER2阴性,并经常表达至少一种基础标志物,例如基础细胞角蛋白或表皮生长因子受体(EGFR)。以前,我们小组使用P-钙黏着蛋白(P-CD),p63和细胞角蛋白5(CK5)在一系列浸润性乳腺癌中鉴定了基底样肿瘤。根据这项研究,我们假设那些高度的基底样浸润性癌可能具有浸润前的对应物,可以使用相同的方法进行鉴别。根据其ER,HER2和基础标志物的表达,将79例导管原位癌(DCIS)分为不同的亚组。 Luminal DCIS表达ER,占该系列的64.6%; HER2过表达的肿瘤不表达ER,占病例的25.3%,而10.1%的患者不表达ER和HER2,并且表达至少一种基础标志物(P-CD,CK5,CK14,p63,波形蛋白和/或EGFR) 。这些基底样DCIS大多是高级别的,具有粉刺型坏死,并始终显示P-CD和CK5的表达。总之,在我们的系列中,具有基底样表型的DCIS占很小的比例,即P-CD和CK5,这是区分乳腺原位癌的最有用的辅助标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号